NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ERBA Diagnostics, Inc. (NYSE:ERB) resulting from allegations that ERBA may have issued materially misleading business information to the investing public.
On November 20, 2015, ERBA disclosed that its previously issued financial statements for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 (collectively, the “Non-Reliance Periods”) should no longer be relied upon. ERBA further disclosed that it intends to restate its financial statements for the Non-Reliance Periods. On this news, shares of ERBA fell $0.27 per share or over 15% to close at $1.47 per share on November 23, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by ERBA investors. If you purchased shares of ERBA on or before November 20, 2015, please visit the firm’s website at http://rosenlegal.com/cases-790.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.